ANI Pharmaceuticals, Inc.
Health
Performance
3.8
Risk
Sell
Buy
Curious about the Scores? Learn more.

ANI Pharmaceuticals, Inc. stock rating and score history

All changes in ratings, performance and outlook tracked over time.

18.09.2026
Short-term strength kicking in. Early signs of life.
17.09.2026
Calmer waters ahead. Risk signals cooling off.
09.08.2026
Losing steam. Solid pieces remain, but cracks are showing.
01.07.2026
Health’s picking up. Numbers look cleaner, cash flow tighter.
ANIP
ANI Pharmaceuticals, Inc.
78.85
+3.56%
3.8
Sell
Buy
ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does ANI Pharmaceuticals, Inc. do? Business model and key facts

Get the full picture of ANI Pharmaceuticals, Inc.: what it builds, where it operates, and how it makes money.

ANI Pharmaceuticals, Inc. Profile

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees (FY): 970

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

shop
Company facts
Nikhil Lalwani
CEO
970
Employees worldwide
shop
Performance
-20.63%
Last 12 months
159.86%
Last 5 years
shop
Growth
$883.37M
Revenue year
$78.34M
Net income
shop
Valuation
$1.73B
Market Cap
22.55
Price/Earnings Ratio

Stocks related to ANI Pharmaceuticals, Inc.

Selected based on industry alignment and relative market positioning.

DVAX
Dynavax Technologies Corporation
15.50
+0.00%
4.8
Sell
Buy
Dynavax Technologies Corporation
PRGO
Perrigo Company plc
14.13
+4.20%
7.9
Sell
Buy
Perrigo Company plc
ALVO
Alvotech
5.88
+0.17%
7.3
Sell
Buy
Alvotech
PAHC
Phibro Animal Health Corporation
34.68
+0.35%
6.7
Sell
Buy
Phibro Animal Health Corporation
CRON
Cronos Group Inc.
3.33
-0.60%
6.0
Sell
Buy
Cronos Group Inc.

Events and news impacting ANI Pharmaceuticals, Inc. stock

Earnings, coporate decisions and industry developments that can affect the share price.

ANI Pharmaceuticals, Inc. fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.